Randomized phase II trials: misleading and unreliable.
Stewart
David J
DJ
D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods / Q000592:standards; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000592:standards; D015986:Confounding Factors, Epidemiologic; D018572:Disease-Free Survival; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D015588:Observer Variation; D011237:Predictive Value of Tests; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards; D012107:Research Design; D012307:Risk Factors; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor